Dr Spero R Cataland (The Ohio State University, Wexner Medical Centre, Columbus, OH, USA) joins us for Rare Disease Day to discuss the importance of rapid diagnosis of acquired thrombotic thrombocytopenic purpura (aTTP), a rare blood disorder in which blood clots form in small blood vessels throughout the body. In this interview, Dr Cataland discusses the risks associated with aTTP, the long-term complications and the impact of living with this disease day to day.
Touch Medical Media is supporting Rare Disease Day (28 February 2022) to shine a light on healthcare inequalities for people living with Rare Diseases, focusing on patient quality of life and the difficulty of diagnosing patients early.
- Could you tell us about acquired/immune TTP and how it impacts patients’ daily lives? (0:35)
- Why is a rapid diagnosis of aTTP important for patients and what are the challenges in achieving this? (4:40)
- What are the current management options for patients with aTTP and what more is needed to prevent long-term complications and prevent relapse? (7:10)
Disclosures: Spero Cataland is a consultant to Sanofi and Takeda.
Support: The production of this video was supported by Touch Medical Media.
Other content available in support of Rare Disease Day includes:
- Damara Ortiz: The impact of Pompe disease and the importance of newborn screening
- Shekita Green: Living with neuromyelitis optica spectrum disorder (NMOSD) – A patient perspective
- Megan Hunter: Living with myasthenia gravis – A journey to diagnosis
- Ethan Crough: Living with achondroplasia – Celebrating diversity and increasing awareness
- Said Beydoun: Understanding myasthenia gravis and the impact on patients’ quality of life
- Jackie Palace: Improving diagnosis and treatment of neuromyelitis optica spectrum disorder
- Richard Keen, Rare Disease Day 2022: Rare bone diseases – Diagnosis, management and patient quality of life
Share this Video
Related Videos In Haematology
Spero R Cataland, Rare Disease Day 2022: Acquired thrombotic thrombocytopenic purpura – Risks, complications and the impact on daily life
Dr Spero R Cataland (The Ohio State University, Wexner Medical Centre, Columbus, OH, USA) joins us for Rare Disease Day to discuss the importance of rapid diagnosis of acquired thrombotic thrombocytopenic purpura (aTTP), a rare blood disorder in which blood clots form in small blood vessels throughout the body. In this interview, Dr Cataland discusses […]
Steven Pipe, ASH 2020 – First Results from the HOPE-B Gene Therapy Trial
We had the pleasure to talk to Steven Pipe (University of Michigan, Ann Arbor, MI, USA) to discuss the use of gene therapy for the treatment of haemophilia B. The abstract ‘First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe […]
Efstathios Kastritis, EHA 2020: CYBORD in Amyloidosis and The ANDROMEDA Study
touchONCOLOGY joins Dr Efstathios Kastritis (Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece) at EHA25 Virtual to discuss the ANDROMEDA study (NCT03201965), and the efficacy and safety of daratumumab in combination with CYBORD for the treatment of newly-diagnosed light chain amyloidosis. Questions: What are the major therapeutic […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!